Control of thyrotoxicosis with sotalol

Ann Clin Res. 1976 Dec;8(6):415-7.


Sotalol, a beta-adrenergic blocking agent devoid of intrinsic sympathicomimetic activity and local anaesthetic properties, was assessed in a double-blind cross-over study for the symptomatic treatment of 10 patients with thyrotoxicosis. The heart rate and clinical thyrotoxicosis index were significantly lower than with the placebo or with no treatment. The values of free thyroxine and triiodothyronine in the serum did not change. Because of its pure beta-adrenergic blocking effect, sotalol is suitable for the symptomatic treatment of thyrotoxicosis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Clinical Trials as Topic
  • Drug Evaluation
  • Heart Rate / drug effects
  • Humans
  • Hyperthyroidism / drug therapy*
  • Sotalol / therapeutic use*


  • Sotalol